Results overview: Found 2 records in 0.02 seconds.
Articles, 2 records found
Articles 2 records found  
1.
14 p, 1.9 MB Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer / Rodón, Jordi (Hospital Universitari Vall d'Hebron) ; Carducci, Michael (Johns Hopkins Kimmel Cancer Center) ; Sepulveda-Sánchez, Juan M. (Hospital Universitario 12 de Octubre) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Calvo, Emiliano (START Madrid, Centro Integral Oncológico Clara Campal) ; Seoane, Joan (Hospital Universitari Vall d'Hebron) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Cleverly, Ann (Eli Lilly and Company) ; Pillay, N. Sokalingum (Eli Lilly and Company) ; Desaiah, Durisala (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Paz-Ares, Luis (Hospital Virgen del Rocío, Sevilla, Spain) ; Holdhoff, Matthias (Johns Hopkins Kimmel Cancer Center) ; Blakeley, Jaishri (Johns Hopkins University) ; Lahn, Michael M. (Eli Lilly and Company) ; Baselga, Jose (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Purpose Transforming growth factor-beta (TGF-β) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-β signaling reverse EMT and arrest tumor progression. [...]
2014 - 10.1007/s10637-014-0192-4
Investigational New Drugs, Vol. 33 (december 2014) , p. 357-370  
2.
16 p, 911.4 KB Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients / Molina, David (Universidad de Castilla-La Mancha (Ciudad Real)) ; Pérez Beteta, Julián (Universidad de Castilla-La Mancha (Ciudad Real)) ; Martínez González, Alicia (Universidad de Castilla-La Mancha (Ciudad Real)) ; Sepúlveda, Juan M. (Hospital Universitario 12 de Octubre (Madrid)) ; Peralta, Sergi (Hospital Universitari Sant Joan de Reus (Tarragona)) ; Gil Gil, Miguel J. (Institut Català d'Oncologia) ; Reynes, Gaspar (Hospital Universitario La Fe (València)) ; Herrero, Ana (Hospital Universitario Miguel Servet (Zaragoza)) ; De Las Peñas, Ramón (Consorci Hospitalari Provincial de Castelló) ; Luque, Raquel (Hospital Universitario Virgen de las Nieves (Granada)) ; Capellades, Jaume (Hospital del Mar (Barcelona)) ; Balañá, Carmen (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Pérez García, Víctor M. (Universidad de Castilla-La Mancha (Ciudad Real))
Background: Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. [...]
2016 - 10.1371/journal.pone.0161484
PloS one, Vol. 11 Núm. 8 (August 2016)  

See also: similar author names
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.